Revisiting the diagnostic and prosnotic performance of cyfra 21-1 and cea in non small cell lung cancer
DOI:
https://doi.org/10.47972/vjcts.v51i.1384Abstract
Introduction: Non-small cell lung cancer (NSCLC), a leading cause of cancer mortality, is often diagnosed late, necessitating reliable biomarkers. Carcinoembryonic Antigen (CEA) and Cytokeratin 19 Fragment (CYFRA 21-1) show promise for early detection and prognosis in NSCLC, but their performance requires further validation. Methods: This retrospective study evaluated 135 patients at a tertiary hospital for lung cancer. Diagnostic performance of CEA and CYFRA 21-1 was assessed via Receiver Operating Characteristic (ROC) analysis, with subgroup analyses across histological subtypes. Survival was analyzed using Kaplan-Meier estimates and Cox proportional hazards models. Results: Of 135 patients, 95 had NSCLC (70.4%). ROC analysis showed moderate diagnostic accuracy for CEA (AUC: 0.78, 95% CI: 0.70–0.85; cut-off: 5.5 ng/mL, sensitivity: 72%, specificity: 68%) and CYFRA 21-1 (AUC: 0.82, 95% CI: 0.75–0.88; cut-off: 3.8 ng/mL, sensitivity: 78%, specificity: 70%). Subgroup analysis revealed CYFRA 21-1’s superior accuracy in squamous cell carcinoma (AUC: 0.87, sensitivity: 82%, specificity: 75%) and adenocarcinoma (AUC: 0.84), while CEA performed better in poorly differentiated carcinoma (AUC: 0.77). Elevated CEA (>5.5 ng/mL) and CYFRA 21-1 (>3.8 ng/mL) predicted worse survival (HR: 1.5, 95% CI: 1.1–2.0; HR: 1.7, 95% CI: 1.2–2.3), reducing median survival to 12 and 10 months from 20 and 22 months, respectively. Conclusion: CEA and CYFRA 21-1 enhance NSCLC diagnosis and prognosis, with histology-specific strengths, supporting their role in precision oncology.Downloads
References
1. Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer. 2013;80(1):45-9. doi:10.1016/j.lungcan.2013.01.002.
2. Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D, et al. Serum tumor markers CEA, CYFRA 21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12(3):172-9. doi:10.1016/j.cllc.2011.03.019.
3. Jiang ZF, Wang M, Xu JL. Prognostic value of serum CYFRA 21-1 in patients with non-small cell lung cancer. J Clin Lab Anal. 2017;31(2):e22029. doi:10.1002/jcla.22029.
4. Zhang Y, Wang L, Li X, et al. Diagnostic value of CYFRA 21-1 and CEA in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2023;12(4):789-801.
5. Chen H, Liu J, Zhao Q, et al. CYFRA 21-1 as a prognostic biomarker in advanced NSCLC: a retrospective cohort study. J Thorac Dis. 2024;16(2):1234-45.
6. Wang R, Zhang J, Li Y, et al. Specificity and sensitivity of CEA and CYFRA 21-1 in lung cancer diagnosis. Clin Chem Lab Med. 2023;61(7):1289-97.
7. Li M, Xu T, Zhang W, et al. Multi-biomarker panels for early detection of NSCLC: a systematic review. Lung Cancer. 2024;189:107456.
8. Kim S, Park J, Lee H, et al. Machine learning-based integration of biomarkers and imaging for lung cancer diagnosis. J Clin Oncol. 2024;42(15):1789-99.
9. Yang Q, Zhou F, Chen X, et al. Prognostic significance of CYFRA 21-1 and CEA in NSCLC patients with metastasis. Cancer Med. 2023;12(8):9345-55.
10. Liu Z, Wu Y, Zhang C, et al. Advances in proteomic and AI-driven biomarker discovery for NSCLC. Front Oncol. 2024;14:1357890.
11. Wang R, Zhang J, Li Y, et al. Specificity and sensitivity of CEA and CYFRA 21-1 in lung cancer diagnosis. Clin Chem Lab Med. 2023;61(7):1289-97.
